¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀå : ±âȸ, ¼ºÀå ÃËÁø¿äÀÎ, »ê¾÷ µ¿Ç⠺м® ¹× ¿¹Ãø(2025-2034³â)
Biopharmaceutical Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
»óǰÄÚµå : 1721417
¸®¼­Ä¡»ç : Global Market Insights Inc.
¹ßÇàÀÏ : 2025³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 145 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,850 £Ü 6,718,000
PDF & Excel (Single User License) help
PDF, Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,050 £Ü 8,381,000
PDF & Excel (Multi User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,350 £Ü 11,567,000
PDF & Excel (Enterprise User License) help
PDF, Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀåÀº 2024³â 4,225¾ï ´Þ·¯·Î Æò°¡µÇ¾ú°í, ¸¸¼º ¹× Èñ±ÍÁúȯÀÇ À¯º´·ü Áõ°¡, »ý¹°ÇÐÀû Á¦Á¦ ¹× Á¤¹Ð Ä¡·á¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î 2034³â¿¡´Â 9,215¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ÃßÁ¤µÇ¸ç, CAGR 8.2%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù. Àü ¼¼°è ÀÇ·á ½Ã½ºÅÛÀÌ °³ÀÎ ¸ÂÃãÇü Ä¡·á·Î ÀüȯÇÔ¿¡ µû¶ó ºÐÀÚ ¼öÁØ¿¡¼­ Áúº´ ¸ÞÄ¿´ÏÁòÀ» Ç¥ÀûÀ¸·Î »ï´Â ¹ÙÀÌ¿ÀÀǾàǰÀÌ Åº·ÂÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ƯÈ÷ À¯ÀüÀÚ ÆíÁý, ¼¼Æ÷ Ä¡·á, Â÷¼¼´ë ´Ü¹éÁú °øÇаú °°Àº ºÐ¾ß¿¡¼­ »ý¸í°øÇÐÀÇ ±Þ¼ÓÇÑ ¹ßÀüÀº ÇѶ§ ºÒÄ¡º´À¸·Î ¿©°ÜÁ³´ø ÁúȯÀ» Ä¡·áÇÒ ¼ö ÀÖ´Â »õ·Î¿î °¡´É¼ºÀ» ¿­¾îÁÖ°í ÀÖ½À´Ï´Ù.

¹ÙÀÌ¿ÀÀǾàǰ Market-IMG1

¶óÀÌÇÁ½ºÅ¸ÀÏ °ü·Ã Áúº´ÀÇ ºÎ´ã Áõ°¡, Àα¸ °í·ÉÈ­, Á¾¾çÇÐ, ½Å°æÇÐ, ¸é¿ªÇÐ ºÐ¾ßÀÇ ¹ÌÃæÁ· ÀÓ»ó ¼ö¿ä Áõ°¡·Î ÀÎÇØ Àü ¼¼°èÀûÀ¸·Î ¼ö¿ä°¡ °è¼Ó Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¤ºÎ¿Í ¹Î°£ ÅõÀÚÀÚµéÀº R&D¿¡ ¸·´ëÇÑ ÀÚº»À» ½ñ¾Æ ºÎÀ¸¸ç Çõ½Å ÆÄÀÌÇÁ¶óÀÎÀ» °­È­ÇÏ°í ½Å¾à °³¹ß ÀÏÁ¤À» ¾Õ´ç±â°í ÀÖ½À´Ï´Ù. ±ÔÁ¦ ±â°üµµ »ý¸íÀ» ±¸ÇÏ´Â Ä¡·áÁ¦¸¦ ´õ »¡¸® ½ÃÀå¿¡ Ãâ½ÃÇϱâ À§ÇØ ½Å¼ÓÇÑ ½ÂÀÎ °æ·Î¸¦ äÅÃÇϰí ÀÖ¾î ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯¿Í µðÁöÅÐ Ä¡·áÁ¦°¡ ÁÖ·ù ÀÇ·á ºÐ¾ß¿¡ ÁøÀÔÇÔ¿¡ µû¶ó ´Ù¾çÇÑ Áö¿ª¿¡¼­ º¹ÀâÇÑ Ä¡·á¹ý¿¡ ´ëÇÑ °æÁ¦¼º°ú Á¢±Ù¼ºÀÌ °³¼±µÇ¾î ¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ºÐ¾ßÀÇ °æÀï ȯ°æÀÌ ÀçÆíµÇ°í ÀÖ½À´Ï´Ù.

½ÃÀå ¹üÀ§
½ÃÀÛ ¿¬µµ 2024³â
¿¹Ãø ¿¬µµ 2025-2034³â
½ÃÀÛ ±Ý¾× 4,225¾ï ´Þ·¯
¿¹Ãø ±Ý¾× 9,215¾ï ´Þ·¯
CAGR 8.2%

¼¼Æ÷ ¹× À¯ÀüÀÚ Ä¡·á¿Í °°Àº »ý¸í°øÇÐÀÇ Çõ½ÅÀº Á¾¾çÇÐ, ¸é¿ªÇÐ, ½Å°æÇÐ ºÐ¾ßÀÇ Ä¡·á ȯ°æÀ» º¯È­½Ã۰í ÀÖ½À´Ï´Ù. ¹ÙÀÌ¿À½Ã¹Ð·¯°¡ ´õ¿í ³Î¸® º¸±ÞµÇ¸é¼­ °æÁ¦¼ºÀÌ °³¼±µÇ°í »ý¸íÀ» ±¸ÇÏ´Â »ý¹°ÇÐÀû Á¦Á¦¿¡ ´ëÇÑ Á¢±Ù¼ºÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. °í°¡ÀÇ »ý¹°ÇÐÀû Á¦Á¦ÀÇ ¹ÙÀÌ¿À½Ã¹Ð·¯ ¹öÀüÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ƯÈ÷ °³¹ßµµ»ó±¹¿¡¼­ ÀǾàǰ Á¢±Ù¼º ¹®Á¦¸¦ ÇØ°áÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, mRNA ±â¼úÀÇ Çõ½ÅÀº Áúº´ ¿¹¹æ ¹× Ä¡·á ÇÁ·ÎÅäÄÝÀ» ÀçÁ¤ÀÇÇÏ¿© ÀÌ ºÐ¾ßÀÇ ºü¸¥ È®Àå¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ½Å¾à °³¹ß ¹× ÀÓ»ó½ÃÇè¿¡ AI¿Í µðÁöÅÐ Ç÷§ÆûÀ» µµÀÔÇÔÀ¸·Î½á ¿î¿µÀ» °£¼ÒÈ­ÇÏ°í ½Å¾à ÆÄÀÌÇÁ¶óÀÎ Àü¹ÝÀÇ ¼º°ø·üÀ» ³ôÀ̰í ÀÖ½À´Ï´Ù.

Á¦Ç° À¯Çüº°·Î, ´ÜÀÏ Å¬·Ð Ç×ü ºÎ¹®Àº ¾Ï, ÀÚ°¡ ¸é¿ª Áúȯ, °¨¿°¼º Áúȯ°ú °°Àº º¹ÀâÇÑ °Ç°­ »óŸ¦ °ü¸®ÇÏ´Â µ¥ ÀÖ¾î ³ôÀº È¿´É°ú ƯÀ̼ºÀ¸·Î ÀÎÇØ 2023³â¿¡ 2,225¾ï ´Þ·¯ÀÇ ¸ÅÃâÀ» ¿Ã·È½À´Ï´Ù. ÀÌ ºÎ¹®ÀÇ °­·ÂÇÑ ½ÃÀå ¼º°ú´Â Áö¼ÓÀûÀÎ ¿¬±¸ °³¹ß, »ý¹°ÇÐÀû ÀǾàǰ¿¡ ´ëÇÑ ½ÂÀÎ Áõ°¡, Ä¡·á ÀÀ¿ë ºÐ¾ßÀÇ È®´ë¿¡ ±âÀÎÇÕ´Ï´Ù. Ç×ü °øÇÐÀÇ Áö¼ÓÀûÀÎ ¹ßÀü°ú ¿©·¯ ÀûÀÀÁõ¿¡ °ÉÄ£ ÀÓ»óÀû Çõ½ÅÀº Àü ¼¼°èÀûÀ¸·Î ´ÜÀÏ Å¬·Ð Ç×ü Ä¡·áÁ¦¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¿ëµµº°·Î´Â Á¾¾çÇÐ ºÎ¹®Àº 2024³â¿¡ 30.9%ÀÇ »ó´çÇÑ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¾Ï Ä¡·á¿¡¼­ ¹ÙÀÌ¿ÀÀǾàǰÀÇ »ç¿ëÀº Ä¡·á¹ýÀÌ ´õ¿í Ç¥ÀûÈ­µÇ°í È¿°úÀûÀÌ µÇ¸é¼­ ºü¸£°Ô È®´ëµÇ°í ÀÖ½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ¾Ï ºÎ´ãÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ºÐÀÚ Á¤¹Ðµµ¿Í ¸é¿ª ü°è Á¶ÀýÀ» Á¦°øÇÏ´Â »ý¹°ÇÐÀû ±â¹Ý Ä¡·á¹ý¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Á¾¾ç ÁøÇàÀ» Â÷´ÜÇÏ°í ¾Ï¼¼Æ÷ ½ÅÈ£¸¦ ¹æÇØÇÏ´Â Çõ½ÅÀûÀÎ Á¢±Ù ¹æ½ÄÀÌ ¾Ï Ä¡·á ÆÐ·¯´ÙÀÓÀ» ÀçÆíÇϸ鼭 ÀÌ ºÎ¹®ÀÇ ¼ºÀåÀ» ´õ¿í ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¹Ì±¹ÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀåÀº 2023³â¿¡ 1,552¾ï ´Þ·¯¸¦ âÃâÇÏ¿´½À´Ï´Ù. ¹Ì±¹Àº °­·ÂÇÑ ±ÔÁ¦ Á¤Ã¥, ÃÖ÷´Ü ¿¬±¸ ÀÎÇÁ¶ó, ¹ÙÀÌ¿ÀÅ×Å© ±â¾÷, °Å´ë Á¦¾à»ç, Çмú ±â°ü °£ÀÇ Çù·ÂÀ» ÅëÇØ ¸®´õ½ÊÀ» À¯ÁöÇϰí ÀÖ½À´Ï´Ù. À¯ÀüÀÚ ÆíÁý, »ý¹°ÇÐÀû Á¦Á¦ ¹× °³ÀÎ ¸ÂÃãÇü ÀǾàǰ¿¡ ´ëÇÑ ÁýÁßÀûÀÎ ¿¬±¸·Î ±Û·Î¹ú ÀÔÁö¸¦ °­È­Çß½À´Ï´Ù. °­·ÂÇÑ R&D ÅõÀÚ¿Í Ã·´Ü Ä¡·á Ç÷§ÆûÀÇ ºü¸¥ µµÀÔÀº Áö¿ª Àüü¿¡¼­ ½ÃÀå È®´ë¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

¼¼°èÀÇ ¹ÙÀÌ¿ÀÀǾàǰ ½ÃÀå¿¡¼­ Ȱ¾àÇÏ´Â ÁÖ¿ä ±â¾÷À¸·Î´Â Merck, Johnson & Johnson, Pfizer, GlaxoSmithKline, Sandoz, Takeda Pharmaceutical, Bayer, Amgen, Sanofi, F. Hoffmann-La Roche, Novartis, AstraZeneca, Novo Nordisk, AbbVie, Biogen, Eli Lilly, Bristol-Myers Squibb µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¾÷µéÀº Á¦Ç° ÆÄÀÌÇÁ¶óÀÎÀ» È®ÀåÇϰí, ¹ÙÀÌ¿ÀÅ×Å© ½ºÅ¸Æ®¾÷À» ÀμöÇϰí, Àü·«Àû ±Û·Î¹ú ÆÄÆ®³Ê½ÊÀ» ¸ÎÀ½À¸·Î½á ½ÃÀå ÀÔÁö¸¦ °­È­Çϰí ÀÖ½À´Ï´Ù. R&D, Ä¡·á¹ý ´Ù°¢È­, ÀÓ»ó½ÃÇè ¹× ¾à¹° Àü´Þ ÃÖÀûÈ­¸¦ À§ÇÑ µðÁöÅÐ ÅëÇÕ¿¡ ´ëÇÑ ÁýÁßÀûÀÎ ÅõÀÚ´Â ¿©ÀüÈ÷ ÃÖ¿ì¼± ¼øÀ§ÀÔ´Ï´Ù. ¿¬±¸ ±â°ü ¹× ÀÇ·á ¼­ºñ½º Á¦°ø¾÷ü¿ÍÀÇ Çù¾÷À» ÅëÇØ ±ÔÁ¦ ½ÂÀÎÀ» °¡¼ÓÈ­Çϰí Çõ½ÅÀûÀÎ Ä¡·á¹ýÀÇ ½ÃÀå Ãâ½Ã ±â°£À» ´ÜÃàÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¾÷°è ÀλçÀÌÆ®

Á¦4Àå °æÀï ±¸µµ

Á¦5Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : Á¦Ç° À¯Çüº°(2021-2034³â)

Á¦6Àå ½ÃÀåÃß°è ¹× ¿¹Ãø : ¿ëµµº°(2021-2034³â)

Á¦7Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : ¾àÁ¦ À¯Çüº°(2021-2034³â)

Á¦8Àå ½ÃÀåÃß°è ¹× ¿¹Ãø : Á¦Á¶ ¾÷Á¾º°(2021-2034³â)

Á¦9Àå ½ÃÀå Ãß°è ¹× ¿¹Ãø : Åõ¿© °æ·Îº°(2021-2034³â)

Á¦10Àå ½ÃÀåÃß°è ¹× ¿¹Ãø : ó¹æÀü À¯Çüº°(2021-2034³â)

Á¦11Àå ½ÃÀåÃß°è ¹× ¿¹Ãø : À¯Åëä³Îº°(2021-2034³â)

Á¦12Àå ½ÃÀåÃß°è ¹× ¿¹Ãø : Áö¿ªº°(2021-2034³â)

Á¦13Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

HBR
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Global Biopharmaceutical Market was valued at USD 422.5 billion in 2024 and is estimated to grow at a CAGR of 8.2% to reach USD 921.5 billion by 2034, driven by the rising prevalence of chronic illnesses and rare diseases, along with increasing demand for biologics and precision therapies. As healthcare systems worldwide shift toward personalized treatment, biopharmaceuticals are gaining momentum for their ability to target disease mechanisms at the molecular level. The rapid advancements in biotechnology-especially in areas like gene editing, cell therapies, and next-gen protein engineering-are unlocking new possibilities for treating conditions once considered incurable.

Biopharmaceutical Market - IMG1

The growing burden of lifestyle-related diseases, aging populations, and unmet clinical needs in oncology, neurology, and immunology continue to propel global demand. Governments and private investors are pouring significant capital into R&D, boosting innovation pipelines and accelerating drug development timelines. Regulatory agencies are also adopting expedited approval pathways to bring life-saving treatments to market faster, further encouraging growth. As biosimilars and digital therapeutics enter mainstream healthcare, affordability and access to complex treatments are improving across various regions, reshaping the competitive landscape of the global biopharmaceutical space.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$422.5 Billion
Forecast Value$921.5 Billion
CAGR8.2%

Breakthroughs in biotechnology, such as cell and gene therapies, are transforming the treatment landscape for conditions in oncology, immunology, and neurology. Biosimilars are becoming more widely available, improving affordability and expanding access to life-saving biologics. The growing availability of biosimilar versions of high-cost biologics is helping address drug accessibility issues, especially in developing markets. Innovations in mRNA technology are also redefining disease prevention and treatment protocols, contributing significantly to the sector's rapid expansion. The adoption of AI and digital platforms in drug discovery and clinical trials is streamlining operations and enhancing success rates across drug pipelines.

By product type, the monoclonal antibodies segment generated USD 225 billion in 2023, owing to their high efficacy and specificity in managing complex health conditions like cancer, autoimmune diseases, and infectious ailments. The strong market performance of this segment is attributed to continuous research and development, increasing approvals for biologic drugs, and broadening therapeutic applications. Ongoing advancements in antibody engineering and clinical breakthroughs across multiple indications are fueling the demand for monoclonal antibody therapies worldwide.

On the application front, the oncology segment held a significant market share of 30.9% in 2024. The use of biopharmaceuticals in cancer care is expanding rapidly as treatments become more targeted and effective. The growing global cancer burden is pushing the demand for biologic-based therapies that offer molecular precision and immune system modulation. Innovative approaches that block tumor progression and interfere with cancer cell signaling are reshaping the cancer treatment paradigm, further driving growth in this segment.

The U.S. Biopharmaceutical Market generated USD 155.2 billion in 2023. Its leadership is supported by robust regulatory policies, cutting-edge research infrastructure, and collaborations among biotech firms, pharmaceutical giants, and academic institutions. The country's focus on gene editing, biologics, and personalized medicine has strengthened its global position. Strong R&D investments and rapid adoption of advanced therapy platforms continue to fuel market expansion across the region.

Key players active in the Global Biopharmaceutical Market include Merck, Johnson & Johnson, Pfizer, GlaxoSmithKline, Sandoz, Takeda Pharmaceutical, Bayer, Amgen, Sanofi, F. Hoffmann-La Roche, Novartis, AstraZeneca, Novo Nordisk, AbbVie, Biogen, Eli Lilly, and Bristol-Myers Squibb. These companies are enhancing their market presence by expanding product pipelines, acquiring biotech startups, and forming strategic global partnerships. Heavy investments in R&D, therapeutic diversification, and digital integration for clinical trials and drug delivery optimization remain top priorities. Collaborations with research institutions and healthcare providers are accelerating regulatory approvals and ensuring faster time-to-market for innovative therapies.

Table of Contents

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Industry Insights

Chapter 4 Competitive Landscape, 2024

Chapter 5 Market Estimates and Forecast, By Product Type, 2021-2034 ($ Mn)

Chapter 6 Market Estimates and Forecast, By Application, 2021-2034 ($ Mn)

Chapter 7 Market Estimates and Forecast, By Drug Type, 2021-2034 ($ Mn)

Chapter 8 Market Estimates and Forecast, By Manufacturing Type, 2021-2034 ($ Mn)

Chapter 9 Market Estimates and Forecast, By Route of Administration, 2021-2034 ($ Mn)

Chapter 10 Market Estimates and Forecast, By Prescription Type, 2021-2034 ($ Mn)

Chapter 11 Market Estimates and Forecast, By Distribution channel, 2021-2034 ($ Mn)

Chapter 12 Market Estimates and Forecast, By Region, 2021-2034 ($ Mn)

Chapter 13 Company Profiles

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â